PubRank

M Broggini

Author PubWeight™ 87.66‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol 2011 1.58
2 Bone mineralization and body composition in young patients with celiac disease. Am J Gastroenterol 1997 1.46
3 Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 2000 1.34
4 p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 1997 1.31
5 In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res 1987 1.26
6 p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res 1997 1.21
7 Abnormalities of peripheral blood T lymphocyte subsets in polymyalgia rheumatica. Clin Exp Rheumatol 1985 1.15
8 CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer 1999 1.13
9 A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. Br J Cancer 2010 1.12
10 Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp Cell Res 1998 1.11
11 Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res 1994 1.10
12 Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 1986 1.10
13 Accumulation of DNA strand breaks in cells exposed to methotrexate or N10-propargyl-5,8-dideazafolic acid. Cancer Res 1988 1.10
14 Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995 1.09
15 Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene 2007 1.06
16 PI3K/AKT/mTOR inhibitors in ovarian cancer. Curr Med Chem 2010 1.03
17 p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene 2001 1.02
18 Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. Cancer Res 1999 1.02
19 Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia 2001 1.00
20 DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. Br J Cancer 1997 0.99
21 Effect of Aplidin in acute lymphoblastic leukaemia cells. Br J Cancer 2003 0.98
22 Antiangiogenic activity of aplidine, a new agent of marine origin. Br J Cancer 2004 0.97
23 Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol 1997 0.97
24 Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies. Int J Cancer 1993 0.96
25 RAS/RAF/MEK inhibitors in oncology. Curr Med Chem 2012 0.96
26 A seasonal pattern in the onset of polymyalgia rheumatica. Ann Rheum Dis 1990 0.94
27 Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines. FASEB J 2000 0.94
28 Differential distribution of antitumor agents in primary and secondary tumors. Cancer Treat Rep 1977 0.93
29 P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line. Cancer Res 2001 0.93
30 In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma. Cancer Chemother Pharmacol 1986 0.93
31 Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage. Clin Cancer Res 1999 0.92
32 DeltaNp63 expression is associated with poor survival in ovarian cancer. Ann Oncol 2007 0.92
33 Effects of nimesulide on pain and on synovial fluid concentrations of substance P, interleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib. Int J Clin Pract 2007 0.91
34 p53 regulates the minimal promoter of the human topoisomerase IIalpha gene. Nucleic Acids Res 1996 0.91
35 Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: possible role of p53. Int J Cancer 1997 0.89
36 Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur J Cancer 2002 0.89
37 Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin. Br J Cancer 1995 0.88
38 Effects of tramadol on synovial fluid concentrations of substance P and interleukin-6 in patients with knee osteoarthritis: comparison with paracetamol. Int Immunopharmacol 2003 0.88
39 Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice. Cancer Treat Rep 1978 0.88
40 Computed radiographic absorptiometry and morphometry in the assessment of postmenopausal bone loss. Osteoporos Int 1996 0.88
41 Development of distamycin-related DNA binding anticancer drugs. Expert Opin Investig Drugs 2001 0.87
42 Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. Br J Cancer 1999 0.87
43 Human ovarian tumors in primary culture: growth, characterization and initial evaluation of the response to cis platinum treatment in vitro. Int J Cancer 1988 0.87
44 Effects of inducible overexpression of DNp73alpha on cancer cell growth and response to treatment in vitro and in vivo. Cell Death Differ 2005 0.86
45 Relapsing-remitting painful ophthalmoplegia due to orbital myositis. J Headache Pain 2005 0.86
46 Microsatellite instability and mutational analysis of transforming growth factor beta receptor type II gene (TGFBR2) in sporadic ovarian cancer. Mol Pathol 2001 0.85
47 HtrA2 enhances the apoptotic functions of p73 on bax. Cell Death Differ 2008 0.85
48 Studies on the comparative distribution and biliary excretion of doxorubicin and 4'-epi-doxorubicin in mice and rats. Cancer Treat Rep 1981 0.85
49 Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517). Br J Cancer 1993 0.85
50 Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice. Cancer Chemother Pharmacol 1982 0.85
51 Problems in the design of anticancer agents. Cancer Surv 1989 0.84
52 Short-term intravenous therapy with Neridronate in Paget's disease. Clin Exp Rheumatol 2002 0.84
53 Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors. Cancer Treat Rep 1984 0.83
54 DNA-topoisomerase I activity and content in epithelial ovarian cancer. Ann Oncol 1998 0.82
55 Microsatellite instability and frameshift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancer. Oncol Res 1999 0.82
56 Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes. Int J Cancer 1995 0.81
57 Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteoporos Int 1993 0.81
58 Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse. Eur J Cancer Clin Oncol 1986 0.81
59 Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53. Ann Oncol 1995 0.81
60 Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743. Eur J Cancer 2005 0.81
61 DNA damage, cytotoxic effect and cell-cycle perturbation of Hoechst 33342 on L1210 cells in vitro. Cytometry 1988 0.81
62 Differential inhibition of the DNA binding of transcription factors NF kappa B and OTF-1 by nitrogen mustard and quinacrine mustard: transcriptional implications. Carcinogenesis 1993 0.81
63 p73 competes with p53 and attenuates its response in a human ovarian cancer cell line. Nucleic Acids Res 2000 0.81
64 Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations. Eur J Cancer 2011 0.81
65 P53-independent caspase-mediated apoptosis in human leukaemic cells is induced by a DNA minor groove binder with antineoplastic activity. Apoptosis 1999 0.80
66 Molecular characterisation of a panel of human ovarian carcinoma xenografts. Eur J Cancer 1998 0.80
67 Defective lymphocyte chemotaxis in patients with AIDS. J Infect Dis 1988 0.80
68 Sequence-specific DNA interactions by novel alkylating anthracycline derivatives. Anticancer Drug Des 1995 0.80
69 O6-methylguanine inhibits the binding of transcription factors to DNA. Nucleic Acids Res 1991 0.80
70 Sequence-specific DNA alkylation of novel tallimustine derivatives. Anticancer Drug Des 1998 0.80
71 DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer. Pharmacogenomics J 2011 0.80
72 The effect of silver ions on copper metabolism and expression of genes encoding copper transport proteins in rat liver. Dokl Biochem Biophys 2008 0.79
73 Low-protein diet prevents glomerular damage in adriamycin-treated rats. Kidney Int 1985 0.79
74 Changes in cyclins and cyclin-dependent kinases induced by DNA damaging agents in a human ovarian cancer cell line expressing mutated or wild-type P53. Exp Cell Res 1996 0.79
75 Anti-hyperalgesic effects of nimesulide: studies in rats and humans. Int J Clin Pract Suppl 2002 0.79
76 Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist. Ann Oncol 2012 0.79
77 The expression of the DeltaNp73beta isoform of p73 leads to tetraploidy. Eur J Cancer 2008 0.78
78 Pharmacokinetics of hexamethylmelamine and pentamethylmelamine in mice. Cancer Treat Rep 1981 0.78
79 New molecules and strategies in the field of anticancer agents. Curr Med Chem Anticancer Agents 2004 0.78
80 Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis. Neoplasia 2000 0.78
81 Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma. Cancer Chemother Pharmacol 1983 0.78
82 Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double blind, parallel group study. J Rheumatol 2000 0.78
83 Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy. Cancer Treat Rep 1981 0.78
84 hMLH1 and hMSH2 expression and BAX frameshift mutations in ovarian cancer cell lines and tumors. Carcinogenesis 1998 0.78
85 Microsatellite instability and genetic alterations in ovarian cancer. Minerva Ginecol 2003 0.77
86 In vitro and ex vivo effects of recent and new macrolide antibiotics on chemotaxis of human polymorphonuclear leukocytes. J Chemother 1991 0.77
87 Multicenter study of the safety/efficacy of misoprostol in the prevention and treatment of NSAID-induced gastroduodenal lesions. Clin Exp Rheumatol 1993 0.77
88 Sun exposure and the polymyalgia rheumatica-giant cell arteritis complex. Clin Exp Rheumatol 1994 0.77
89 Plasma and synovial fluid concentrations of nimesulide and its main metabolite after a single or repeated oral administration in patients with knee osteoarthritis. J Int Med Res 2006 0.77
90 Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours. Br J Cancer 1997 0.77
91 Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor. Cancer Res 1987 0.77
92 DNA Damage Induces p53-dependent Down-regulation of hCHK1. J Biol Chem 2001 0.77
93 Influence of tumor on adriamycin concentration in blood cells. Cancer Chemother Pharmacol 1980 0.77
94 L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives. Br J Cancer 1994 0.77
95 Alpha-bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity. Br J Cancer 1999 0.77
96 Serum levels of gamma interferon in patients with Down's syndrome. Infection 1995 0.77
97 A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. Drugs 2003 0.76
98 Transplacental passage of doxorubicin. Lancet 1983 0.76
99 Characterization of a protein recognizing minor groove binders-damaged DNA. Nucleic Acids Res 1996 0.76
100 Cis dichlorodiammine platinum induced DNA interstrand cross-links in primary cultures of human ovarian cancer. Br J Cancer 1991 0.75
101 Diclofenac sodium in biliary colic: a double blind trial. Br Med J (Clin Res Ed) 1984 0.75
102 Body composition and growth in asthmatic children treated with inhaled steroids. Ann Allergy Asthma Immunol 2000 0.75
103 Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice. Cancer Treat Rep 1982 0.75
104 Effect of rokitamycin on human polymorphonuclear leukocyte chemotaxis. Int J Tissue React 1989 0.75
105 Biodegradable microcarriers as cell delivery vehicle for in vivo transplantation and magnetic resonance monitoring. J Biol Regul Homeost Agents 2011 0.75
106 [Study of intestinal absorption of calcium using 47Ca and whole body counter in renal calculosis with hypercalciuria]. Ann Ital Med Int 1990 0.75
107 [Sodium diclofenac in ureteral colic. Comparative double-blind study with placebo]. Minerva Urol Nefrol 1986 0.75
108 Allelic expression of p73 in human ovarian cancers. Ann Oncol 1999 0.75
109 [Ultrasonic and computer tomography diagnosis of schwannoma of the tibial nerve. Description of a case]. Radiol Med 1990 0.75
110 The assessment of quality of life as a measure of gold salts treatment efficacy in rheumatoid arthritis. Minerva Med 2002 0.75
111 [Gout in Valchiavenna in the XVII century: a case report]. Reumatismo 2007 0.75
112 Biochemical studies on the ability of pentamethylmelamine to interact in vivo with DNA and proteins in a sensitive murine ovarian reticular cell sarcoma. Biochem Pharmacol 1984 0.75
113 Subcellular distribution of adriamycin in the liver and tumor of 3LL-bearing mice. Eur J Cancer Clin Oncol 1983 0.75
114 The diffusion of pirprofen into the cerebrospinal fluid in man. Eur J Clin Pharmacol 1988 0.75
115 Pharmacokinetics of oxatomide given percutaneously to healthy volunteers. Biopharm Drug Dispos 1992 0.75
116 Comparative metabolism of daunorubicin and 4-demethoxydaunorubicin in mice and rabbits. Cancer Treat Rep 1986 0.75
117 p53Transfectants in Ovarian Cancer. Methods Mol Med 2001 0.75
118 Differential expression of c-fos proto-oncogene in two subclones derived from a human ovarian cancer cell line. Cell Mol Biol (Noisy-le-grand) 1995 0.75
119 [Esophageal function remains unchanged in systemic sclerosis at four years of follow-up]. Minerva Gastroenterol Dietol 2003 0.75
120 Studies of the mode of action of antitumour triazenes and triazines-III. Metabolism studies on hexamethylmelamine. Biochem Pharmacol 1982 0.75
121 Central side effects of pentamethylmelamine: biochemical and behavioural studies. Biochem Pharmacol 1984 0.75
122 Skin testing to predict immune response to hepatitis B vaccine. Lancet 1985 0.75
123 Notes on the use of in vitro systems to investigate the activity and the mechanism of action of antineoplastic agents. Cytotechnology 1991 0.75
124 Horseradish peroxidase/hydrogen peroxide-catalyzed oxidation of VP16-213. Identification of a new metabolite. Chem Biol Interact 1985 0.75
125 The pharmacokinetics of clotiazepam after oral and sublingual administration to volunteers. Eur J Clin Pharmacol 1989 0.75
126 Hepatitis B and C infection in an institution for the mentally handicapped. Infection 1994 0.75
127 IFN-beta partially counteracts inhibition of natural killer activity induced by some antitumor agents. J Interferon Cytokine Res 1998 0.75
128 Extranodal marginal zone B-cell lymphoma genotyping by Alu-polymerase chain reaction. Leuk Lymphoma 2000 0.75
129 Early DNA damage induced in cells exposed to N10-propargyl 5,8-dideazafolic acid (CB 3717) or methotrexate. Biochem Pharmacol 1988 0.75
130 Age-related response to hepatitis B vaccine in the mentally retarded. Lancet 1984 0.75
131 [Sodium gold thiosulfate therapy: an open, viewed, multicenter trial in rheumatoid arthritis patients followed for two years]. Reumatismo 2002 0.75
132 Effect of G:C-->A:T transition, potentially arising from O6-guanine alkylation, in the transcription regulation of c-fos serum response element. Anticancer Res 1997 0.75
133 Correction to Lancet Oncol 2015; 16: 747. EGFR mutations and EGFR tyrosine kinase inhibitors. Lancet Oncol 2015 0.75
134 [Sarcoidosis of oculo-parotid onset. Differential diagnostic considerations]. Minerva Med 1986 0.75
135 Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice. Cancer Treat Rep 1983 0.75
136 [Wernicke-Korsakoff syndrome caused by prolonged infusion therapy during the postoperative period]. Recenti Prog Med 1991 0.75
137 Differential adriamycin distribution to blood components. Eur J Drug Metab Pharmacokinet 1981 0.75
138 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms. Cancer Res 2001 0.75
139 The inhibition of supercoiling activity of DNA gyrase from Micrococcus luteus caused by rufloxacin (MF 934) and MF 961. J Antimicrob Chemother 1991 0.75
140 Hepatobiliary metabolism and urinary excretion of 4-demethoxydaunorubicin as compared to daunorubicin in rats. Anticancer Res 1988 0.75
141 Renal involvement in tuberous sclerosis. Adv Exp Med Biol 1989 0.75
142 Prostaglandin and thromboxane synthesis by Lewis lung carcinoma during growth. Cancer Res 1985 0.75
143 Chromosome changes in lymphocytes of patients with scleroderma. Ann Genet 1995 0.75
144 Duration of immunity to hepatitis B vaccination in institutionalized mentally retarded patients. Vaccine 1989 0.75
145 [New etiopathologic and therapeutic perspectives in ureteral colic. Evaluation of clinical experience with diclofenac sodium and indomethacin]. Recenti Prog Med 1986 0.75
146 [Association of Lynch syndrome and non-Hodgkin's malignant lymphoma. A case report]. Recenti Prog Med 1999 0.75
147 [Agranulocytosis caused by dipyrone. Case reports]. Clin Ter 1989 0.75
148 Flurbiprofen versus ASA in influenza symptomatology: a double-blind study. Int J Clin Pharmacol Res 1986 0.75
149 Effects of DNA damaging agents on gene expression in two human cancer cell lines. Cell Mol Biol (Noisy-le-grand) 1993 0.75
150 Study on the control of hepatitis B virus infection in an institution for the mentally retarded. Boll Ist Sieroter Milan 1983 0.75
151 Adriamycin distribution in plasma and blood cells of cancer patients with altered hematocrit. Eur J Cancer Clin Oncol 1981 0.75
152 Routes of elimination of hexamethylmelamine and pentamethylmelamine in the rat. Xenobiotica 1982 0.75